OncoMatch/Clinical Trials/NCT06835972
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
Is NCT06835972 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including Abemaciclib and Cabozantinib for metastatic renal cell carcinoma.
Treatment: Abemaciclib · Cabozantinib — The researchers are doing this study to find out whether the combination of abemaciclib and cabozantinib is a safe and effective treatment for people with metastatic clear cell renal cell carcinoma (ccRCC) and translocation-associated renal cell cancer (tRCC). The researchers will test different doses of the study drugs to find the highest doses that cause few or mild side effects in participants.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Renal Cell Carcinoma
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy
must have received prior therapy with at least 2 approved systemic agents and a maximum of 3 prior lines of systemic therapy. Prior adjuvant therapy is permitted.
Must have received: anti-PD-1 therapy
must have progressed on 1 prior PD-1 or PD-L1 targeted treatment
Must have received: VEGFR inhibitor
must have progressed on ... prior VEGFR directed TKI therapy
Cannot have received: CDK4/6 inhibitor (abemaciclib)
Prior treatment with abemaciclib
Cannot have received: VEGFR inhibitor (cabozantinib)
Prior treatment with cabozantinib
Lab requirements
Blood counts
ANC ≥ 1500/μL (no G-CSF within 2 weeks); WBC ≥ 2500/μL and ≤ 15,000/μL; absolute lymphocyte count > 0.5K/mcL; platelets ≥ 100,000/μL (no transfusion within 2 weeks); hemoglobin ≥ 9.0 g/dL (no transfusion within 2 weeks)
Kidney function
eGFR ≥ 30 mL/min (CKD-EPI); urine protein/creatinine ratio ≤ 1.8 mg/mg
Liver function
ALT, AST, ALP ≤ 3 X ULN (ALP ≤ 5 x ULN if bone mets); serum bilirubin ≤ 1.5 x ULN (≤ 2 x ULN if Gilbert disease); serum albumin ≥ 2.8 g/dl
Cardiac function
QTcF ≤ 470 ms by ECG; LVEF ≥ 50% by ECHO
Adequate hematologic and end organ function, defined by the following laboratory results obtained within 14 days prior to the first study treatment: ... ALT, AST, ALP ≤ 3 X ULN (ALP ≤ 5 x ULN if bone mets); serum bilirubin ≤ 1.5 x ULN (≤ 2 x ULN if Gilbert disease); serum albumin ≥ 2.8 g/dl; eGFR ≥ 30 mL/min (CKD-EPI); urine protein/creatinine ratio ≤ 1.8 mg/mg; ANC ≥ 1500/μL (no G-CSF within 2 weeks); WBC ≥ 2500/μL and ≤ 15,000/μL; absolute lymphocyte count > 0.5K/mcL; platelets ≥ 100,000/μL (no transfusion within 2 weeks); hemoglobin ≥ 9.0 g/dL (no transfusion within 2 weeks); QTcF ≤ 470 ms by ECG; LVEF ≥ 50% by ECHO
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Johns Hopkins University (Data Collection Only) · Baltimore, Maryland
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities) · Commack, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06835972 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CDK4/6 inhibitor, VEGFR inhibitor disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages